NASDAQ:SAGE - Sage Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $84.05
  • Forecasted Upside: 17.54 %
  • Number of Analysts: 18
  • Breakdown:
  • 0 Sell Ratings
  • 6 Hold Ratings
  • 12 Buy Ratings
  • 0 Strong Buy Ratings
$71.51
▲ +0.69 (0.97%)
1 month | 3 months | 12 months
Get New Sage Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SAGE and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SAGE

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$84.05
▲ +17.54% Upside Potential
This price target is based on 18 analysts offering 12 month price targets for Sage Therapeutics in the last 3 months. The average price target is $84.05, with a high forecast of $263.00 and a low forecast of $28.00. The average price target represents a 17.54% upside from the last price of $71.51.
Buy
The current consensus among 18 polled investment analysts is to buy stock in Sage Therapeutics.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 11 buy ratings
  • 3 hold ratings
  • 0 sell ratings
5/3/2019
  • 0 strong buy ratings
  • 13 buy ratings
  • 3 hold ratings
  • 0 sell ratings
8/1/2019
  • 0 strong buy ratings
  • 11 buy ratings
  • 4 hold ratings
  • 0 sell ratings
10/30/2019
  • 0 strong buy ratings
  • 13 buy ratings
  • 5 hold ratings
  • 0 sell ratings
1/28/2020
  • 0 strong buy ratings
  • 12 buy ratings
  • 6 hold ratings
  • 0 sell ratings
4/27/2020
  • 0 strong buy ratings
  • 11 buy ratings
  • 6 hold ratings
  • 0 sell ratings
7/26/2020
  • 0 strong buy ratings
  • 12 buy ratings
  • 6 hold ratings
  • 0 sell ratings
9/24/2020
  • 0 strong buy ratings
  • 12 buy ratings
  • 6 hold ratings
  • 0 sell ratings
10/24/2020

Latest Recommendations

  • 0 strong buy ratings
  • 12 buy ratings
  • 6 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/20/2020Royal Bank of CanadaBoost Price TargetOutperform$75.00 ➝ $84.00Low
i
Rating by Brian Abrahams at Royal Bank of Canada
10/16/2020BMO Capital MarketsBoost Price TargetPositive ➝ Outperform$65.00 ➝ $79.00High
i
9/11/2020CitigroupBoost Price TargetPositive ➝ Buy$54.00 ➝ $67.00Low
i
9/11/2020WedbushUpgradeNeutral ➝ Outperform$40.00 ➝ $65.00Low
i
Rating by L. Chico at Wedbush
8/24/2020Morgan StanleyBoost Price TargetOverweight$85.00 ➝ $87.00Medium
i
8/11/2020Royal Bank of CanadaReiterated RatingBuyMedium
i
Rating by Brian Abrahams at Royal Bank of Canada
8/11/2020OppenheimerBoost Price TargetOutperform$50.00 ➝ $65.00High
i
8/10/2020Raymond JamesUpgradeMarket Perform ➝ Outperform$70.00Low
i
8/10/2020MizuhoReiterated RatingHold$44.00High
i
5/26/2020Royal Bank of CanadaBoost Price TargetOutperform$72.00 ➝ $75.00Low
i
Rating by Brian Abrahams at Royal Bank of Canada
5/8/2020SunTrust BanksLower Price TargetHold$37.00 ➝ $35.00High
i
5/8/2020Royal Bank of CanadaBoost Price TargetOutperform$71.00 ➝ $72.00High
i
Rating by Brian Abrahams at Royal Bank of Canada
5/8/2020WedbushDowngradeOutperform ➝ Neutral$36.00 ➝ $37.00Medium
i
Rating by L. Chico at Wedbush
5/8/2020MizuhoBoost Price TargetNeutral$36.00 ➝ $44.00Medium
i
Rating by Vamil Divan at Mizuho
4/28/2020Royal Bank of CanadaBoost Price TargetOutperform$68.00 ➝ $71.00High
i
Rating by Brian Abrahams at Royal Bank of Canada
4/19/2020GuggenheimDowngradeBuy ➝ NeutralHigh
i
4/9/2020BMO Capital MarketsLower Price TargetOutperform$86.00 ➝ $65.00Medium
i
4/9/2020SunTrust BanksLower Price TargetHold$40.00 ➝ $37.00Medium
i
4/8/2020Canaccord GenuityLower Price TargetBuy$96.00 ➝ $80.00Low
i
4/8/2020Royal Bank of CanadaBoost Price TargetOutperform$60.00 ➝ $68.00High
i
Rating by Brian Abrahams at Royal Bank of Canada
4/8/2020WedbushLower Price TargetOutperform$56.00 ➝ $36.00High
i
4/8/2020OppenheimerLower Price TargetOutperform$60.00 ➝ $50.00High
i
4/8/2020CitigroupBoost Price TargetBuy$48.00 ➝ $54.00High
i
Rating by Neena Bitritto-Garg at Citigroup Inc.
4/8/2020GuggenheimDowngradeBuy ➝ NeutralHigh
i
4/8/2020MizuhoLower Price TargetNeutral$58.00 ➝ $36.00High
i
Rating by Vamil Divan at Mizuho
3/26/2020SunTrust BanksLower Price TargetHold$50.00 ➝ $40.00Medium
i
3/22/2020HC WainwrightReiterated RatingHold$78.00Low
i
Rating by Douglas Tsao at HC Wainwright
3/20/2020LADENBURG THALM/SH SHReiterated RatingHold$28.00High
i
3/19/2020OppenheimerLower Price Target$97.00 ➝ $60.00Low
i
3/19/2020SVB LeerinkBoost Price TargetMarket Perform$45.00 ➝ $63.00Low
i
Rating by Marc Goodman at SVB Leerink LLC
3/19/2020GuggenheimLower Price TargetBuy$85.00 ➝ $65.00Low
i
3/19/2020CitigroupLower Price TargetBuy$71.00 ➝ $48.00Low
i
Rating by Neena Bitritto-Garg at Citigroup Inc.
3/18/2020Royal Bank of CanadaUpgradeSector Perform ➝ Outperform$73.00 ➝ $60.00High
i
Rating by Brian Abrahams at Royal Bank of Canada
3/11/2020MizuhoReiterated RatingHold$58.00High
i
Rating by Vamil Divan at Mizuho
3/5/2020CitigroupInitiated CoverageBuy$71.00High
i
3/3/2020Morgan StanleyLower Price TargetOverweight$125.00 ➝ $117.00Medium
i
Rating by Matthew Harrison at Morgan Stanley
2/28/2020SunTrust BanksLower Price TargetHold$60.00 ➝ $50.00High
i
2/28/2020LADENBURG THALM/SH SHReiterated RatingHold$52.00High
i
2/28/2020HC WainwrightLower Price TargetNeutral$87.00 ➝ $78.00High
i
Rating by Douglas Tsao at HC Wainwright
2/28/2020MizuhoLower Price TargetNeutral$69.00 ➝ $58.00High
i
Rating by Vamil Divan at Mizuho
2/27/2020CowenReiterated RatingBuy$96.00High
i
2/27/2020MizuhoReiterated RatingHold$69.00High
i
Rating by Vamil Divan at Mizuho
2/5/2020MizuhoInitiated CoverageNeutral$69.00Low
i
1/7/2020Bank of AmericaBoost Price Target$85.00 ➝ $98.00Medium
i
12/6/2019OppenheimerLower Price Target$190.00 ➝ $100.00Medium
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
12/6/2019JPMorgan Chase & Co.Lower Price TargetOverweight$200.00 ➝ $105.00Low
i
Rating by Cory Kasimov at JPMorgan Chase & Co.
12/6/2019LADENBURG THALM/SH SHDowngradeBuy ➝ NeutralLow
i
12/6/2019Royal Bank of CanadaLower Price TargetOutperform$190.00 ➝ $100.00High
i
Rating by Brian Abrahams at Royal Bank of Canada
12/6/2019Morgan StanleyLower Price TargetOverweight$217.00 ➝ $125.00High
i
12/6/2019BMO Capital MarketsReiterated RatingOutperform$92.00High
i
12/6/2019SVB LeerinkUpgradeUnderperform ➝ Market PerformHigh
i
Rating by M. Goodman at SVB Leerink LLC
12/6/2019HC WainwrightLower Price TargetNeutral$160.00 ➝ $87.00High
i
Rating by D. Tsao at HC Wainwright
12/5/2019Goldman Sachs GroupLower Price Target$227.00 ➝ $263.00High
i
12/5/2019Piper Jaffray CompaniesLower Price TargetOverweight$206.00 ➝ $125.00High
i
12/5/2019GuggenheimLower Price TargetBuy$200.00 ➝ $110.00High
i
12/5/2019CowenReiterated RatingBuy$96.00High
i
12/5/2019Royal Bank of CanadaDowngradeOutperform ➝ Sector Perform$73.00High
i
Rating by Brian Abrahams at Royal Bank of Canada
12/5/2019WedbushLower Price TargetOutperform$203.00 ➝ $90.00High
i
12/5/2019SunTrust BanksDowngradeBuy ➝ Hold$210.00 ➝ $70.00High
i
11/25/2019Royal Bank of CanadaReiterated RatingBuy$235.00Low
i
Rating by Brian Abrahams at Royal Bank of Canada
11/24/2019Morgan StanleyReiterated RatingBuy$217.00Medium
i
11/20/2019Stifel NicolausReiterated RatingBuyLow
i
Rating by Paul Matteis at Stifel Nicolaus
10/30/2019HC WainwrightInitiated CoverageNeutral$160.00Low
i
Rating by D. Tsao at HC Wainwright
8/7/2019OppenheimerLower Price TargetOutperform$200.00 ➝ $190.00Medium
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
7/25/2019OppenheimerBoost Price Target$170.00 ➝ $200.00Medium
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
7/24/2019JPMorgan Chase & Co.Reiterated RatingBuyLow
i
Rating by Cory Kasimov at JPMorgan Chase & Co.
7/24/2019William BlairReiterated RatingBuyLow
i
Rating by Tim Lugo at William Blair
5/22/2019WedbushInitiated CoverageOutperform ➝ Outperform$207.00Low
i
Rating by L. Chico at Wedbush
5/5/2019OppenheimerSet Price TargetBuy$170.00Medium
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
5/2/2019LADENBURG THALM/SH SHSet Price TargetBuy$220.00Low
i
Rating by Michael Higgins at LADENBURG THALM/SH SH
4/26/2019Raymond JamesReiterated RatingMarket PerformMedium
i
4/25/2019Jefferies Financial GroupInitiated CoverageBuy ➝ Buy$195.00Low
i
4/8/2019Canaccord GenuitySet Price TargetBuy$220.00Low
i
Rating by Sumant Kulkarni at Canaccord Genuity
2/22/2019GuggenheimInitiated CoverageBuy$205.00High
i
12/19/2018Morgan StanleyLower Price TargetOverweight ➝ Overweight$230.00 ➝ $213.00High
i
12/14/2018Wolfe ResearchInitiated CoverageOutperform ➝ OutperformMedium
i
12/11/2018LADENBURG THALM/SH SHSet Price TargetBuy$210.00High
i
Rating by Michael Higgins at LADENBURG THALM/SH SH
11/20/2018OppenheimerSet Price TargetBuy$170.00Low
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
11/12/2018SVB LeerinkInitiated CoverageUnderperform$80.00High
i
Rating by M. Goodman at SVB Leerink LLC
11/6/2018JPMorgan Chase & Co.Set Price TargetBuy$205.00Medium
i
Rating by Cory Kasimov at JPMorgan Chase & Co.
11/5/2018Royal Bank of CanadaBoost Price TargetOutperform ➝ Outperform$259.00 ➝ $261.00Medium
i
11/4/2018OppenheimerSet Price TargetBuy$170.00High
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
11/1/2018Canaccord GenuitySet Price TargetBuy$220.00High
i
Rating by Sumant Kulkarni at Canaccord Genuity
11/1/2018CowenReiterated RatingBuy$207.00High
i
10/31/2018LADENBURG THALM/SH SHSet Price TargetBuy$235.00High
i
Rating by Michael Higgins at LADENBURG THALM/SH SH
10/29/2018OppenheimerSet Price TargetBuy$170.00High
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
10/17/2018OppenheimerInitiated CoverageBuy$170.00Medium
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
10/11/2018Morgan StanleyBoost Price TargetOverweight$228.00 ➝ $230.00High
i
10/10/2018OppenheimerInitiated CoverageBuy$170.00Low
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
8/8/2018Canaccord GenuitySet Price TargetBuy$220.00Low
i
Rating by Sumant Kulkarni at Canaccord Genuity
8/7/2018Stifel NicolausBoost Price TargetBuy$198.00 ➝ $239.00Medium
i
8/6/2018Piper Jaffray CompaniesInitiated CoverageOverweight$206.00Medium
i
7/13/2018Morgan StanleyBoost Price TargetOverweight$225.00 ➝ $228.00Low
i
6/14/2018CowenReiterated RatingBuy$207.00Medium
i
6/12/2018Canaccord GenuityReiterated RatingBuy ➝ Buy$220.00High
i
Rating by Sumant Kulkarni at Canaccord Genuity
6/6/2018LADENBURG THALM/SH SHInitiated CoverageBuy$230.00High
i
5/3/2018Canaccord GenuityReiterated RatingBuy$210.00Low
i
Rating by Sumant Kulkarni at Canaccord Genuity
5/3/2018CowenReiterated RatingBuyLow
i
3/26/2018Canaccord GenuityReiterated RatingBuy ➝ Buy$210.00High
i
Rating by Sumant Kulkarni at Canaccord Genuity
3/20/2018CowenReiterated RatingBuy$202.00Low
i
2/28/2018SunTrust BanksBoost Price TargetBuy$203.00Low
i
Rating by Edward Nash at SunTrust Banks, Inc.
2/26/2018Morgan StanleyInitiated CoverageOverweight ➝ Overweight$225.00Low
i
2/23/2018Needham & Company LLCReiterated RatingBuy$193.00Low
i
Rating by Danielle Brill at Needham & Company LLC
1/10/2018JPMorgan Chase & Co.Reiterated RatingBuyHigh
i
12/11/2017CowenReiterated RatingBuyLow
i
12/8/2017Stifel NicolausReiterated RatingBuy$198.00Low
i
Rating by Keith Gay at Stifel Nicolaus
12/8/2017SunTrust BanksBoost Price TargetPositive$178.00High
i
Rating by Edward Nash at SunTrust Banks, Inc.
12/8/2017JPMorgan Chase & Co.Reiterated RatingOverweight$198.00High
i
12/7/2017Raymond JamesReiterated RatingBuy$206.00High
i
Rating by Laura Chico at Raymond James
12/7/2017Canaccord GenuitySet Price TargetBuy ➝ Buy$140.00 ➝ $191.00High
i
Rating by John Newman at Canaccord Genuity
12/7/2017Needham & Company LLCBoost Price TargetBuy ➝ Buy$100.00 ➝ $193.00High
i
Rating by Danielle Brill at Needham & Company LLC
12/7/2017SVB LeerinkBoost Price Target$123.00 ➝ $246.00High
i
12/7/2017BMO Capital MarketsReiterated RatingOutperform$203.00High
i
12/7/2017Royal Bank of CanadaBoost Price TargetOutperform ➝ Sell$137.00 ➝ $280.00High
i
11/27/2017Royal Bank of CanadaLower Price TargetOutperform$145.00 ➝ $137.00Medium
i
11/17/2017BMO Capital MarketsReiterated RatingOutperform$85.67 ➝ $112.00N/A
i
11/16/2017Bank of AmericaLower Price TargetBuy$103.00 ➝ $101.00N/A
i
11/15/2017SunTrust BanksBoost Price TargetBuy ➝ Positive$116.00N/A
i
Rating by Edward Nash at SunTrust Banks, Inc.
11/10/2017Needham & Company LLCBoost Price TargetBuy ➝ Buy$86.00 ➝ $100.00N/A
i
Rating by Danielle Brill at Needham & Company LLC
11/10/2017Chardan CapitalUpgradeNeutral ➝ Buy$60.00 ➝ $140.00N/A
i
Rating by G. Amusa at Chardan Capital
11/9/2017Raymond JamesBoost Price TargetBuy$109.00N/A
i
11/9/2017Stifel NicolausBoost Price TargetBuy$91.00 ➝ $105.00N/A
i
Rating by Keith Gay at Stifel Nicolaus
11/9/2017Royal Bank of CanadaBoost Price TargetOutperform$145.00N/A
i
11/9/2017SVB LeerinkBoost Price TargetOutperform ➝ Positive$85.00 ➝ $123.00N/A
i
11/2/2017Royal Bank of CanadaBoost Price Target$117.00 ➝ $120.00N/A
i
10/27/2017BMO Capital MarketsReiterated RatingBuy$80.00N/A
i
10/19/2017SunTrust BanksSet Price TargetBuy$82.00N/A
i
Rating by Edward Nash at SunTrust Banks, Inc.
10/18/2017Royal Bank of CanadaReiterated RatingBuy$117.00N/A
i
10/6/2017Goldman Sachs GroupReiterated RatingBuy ➝ Buy$87.00N/A
i
9/14/2017Royal Bank of CanadaInitiated CoverageOutperform ➝ Outperform$117.00Medium
i
9/14/2017BMO Capital MarketsBoost Price TargetOutperform$80.00 ➝ $84.00High
i
9/13/2017Chardan CapitalReiterated RatingHoldHigh
i
9/13/2017Needham & Company LLCLower Price TargetBuy ➝ Buy$95.00 ➝ $86.00High
i
Rating by Danielle Brill at Needham & Company LLC
9/13/2017Stifel NicolausReiterated RatingBuy$104.00 ➝ $91.00High
i
Rating by Keith Gay at Stifel Nicolaus
9/13/2017SunTrust BanksReiterated RatingBuy$95.00 ➝ $82.00High
i
9/12/2017Canaccord GenuityLower Price TargetBuy$110.00 ➝ $81.00High
i
Rating by John Newman at Canaccord Genuity
9/12/2017JPMorgan Chase & Co.Lower Price TargetOverweight$99.00 ➝ $85.00High
i
Rating by Cory Kasimov at JPMorgan Chase & Co.
9/12/2017CowenLower Price TargetOutperform$100.00 ➝ $90.00Medium
i
8/31/2017JPMorgan Chase & Co.Reiterated RatingBuyLow
i
Rating by Cory Kasimov at JPMorgan Chase & Co.
8/9/2017Stifel NicolausInitiated CoverageBuy$104.00Low
i
8/5/2017Canaccord GenuitySet Price TargetBuy$110.00Medium
i
Rating by John Newman at Canaccord Genuity
8/4/2017CowenReiterated RatingBuy$100.00Medium
i
8/4/2017Needham & Company LLCSet Price TargetBuy$82.00 ➝ $95.00High
i
Rating by Danielle Brill at Needham & Company LLC
8/4/2017HC WainwrightBoost Price TargetNeutral$86.00High
i
Rating by C. Werther at HC Wainwright
7/28/2017BMO Capital MarketsReiterated RatingBuy$82.00Medium
i
Rating by Gary Nachman at BMO Capital Markets
7/14/2017Stifel NicolausReiterated RatingBuy$90.00Medium
i
6/20/2017SVB LeerinkReiterated RatingOutperform$90.00 ➝ $97.00High
i
6/13/2017Needham & Company LLCReiterated RatingBuy$82.00Medium
i
6/12/2017CowenInitiated CoverageOutperform$95.00Low
i
5/15/2017Needham & Company LLCInitiated CoverageBuy ➝ Buy$82.00Low
i
5/12/2017Bank of AmericaInitiated CoverageBuy ➝ Buy$85.00High
i
5/10/2017Canaccord GenuityReiterated RatingBuy$110.00Medium
i
Rating by John Newman at Canaccord Genuity
4/12/2017Canaccord GenuitySet Price TargetBuy$110.00High
i
Rating by John Newman at Canaccord Genuity
4/3/2017JPMorgan Chase & Co.Reiterated RatingBuy$83.00High
i
Rating by Cory Kasimov at JPMorgan Chase & Co.
3/21/2017Canaccord GenuityReiterated RatingBuy$110.00High
i
Rating by John Newman at Canaccord Genuity
3/6/2017Canaccord GenuitySet Price TargetBuy$110.00N/A
i
Rating by John Newman at Canaccord Genuity
2/23/2017Canaccord GenuitySet Price TargetBuy$110.00N/A
i
Rating by John Newman at Canaccord Genuity
2/22/2017HC WainwrightDowngradeBuy ➝ Neutral$56.00 ➝ $76.00N/A
i
Rating by C. Werther at HC Wainwright
2/22/2017BMO Capital MarketsBoost Price TargetOutperform$68.00 ➝ $82.00N/A
i
Rating by Gary Nachman at BMO Capital Markets
2/14/2017Chardan CapitalUpgradeSell ➝ Neutral$60.00N/A
i
2/13/2017CowenReiterated RatingBuy$95.00N/A
i
2/13/2017BMO Capital MarketsSet Price TargetOutperform ➝ Buy$68.00N/A
i
1/11/2017JPMorgan Chase & Co.Reiterated RatingBuyN/A
i
Rating by Cory Kasimov at JPMorgan Chase & Co.
12/15/2016JPMorgan Chase & Co.Reiterated RatingBuy$74.00N/A
i
Rating by Cory Kasimov at JPMorgan Chase & Co.
12/14/2016Canaccord GenuitySet Price TargetBuy$110.00N/A
i
Rating by John Newman at Canaccord Genuity
12/14/2016Raymond JamesUpgradeOutperform ➝ Strong-Buy$84.00N/A
i
12/14/2016UBS GroupUpgradeOutperform ➝ Strong-BuyN/A
i
12/6/2016Canaccord GenuityReiterated RatingBuy$110.00N/A
i
Rating by john newman at Canaccord Genuity
11/14/2016Stifel NicolausInitiated CoverageBuy$90.00N/A
i
11/3/2016CowenReiterated RatingBuyN/A
i
Rating by Ritu Baral at Cowen Inc
10/4/2016SVB LeerinkReiterated RatingOutperform$68.00N/A
i
Rating by Paul Matteis at SVB Leerink LLC
9/19/2016CowenReiterated RatingBuyN/A
i
Rating by Ritu Baral at Cowen Inc
9/13/2016Raymond JamesInitiated CoverageOutperform$75.00N/A
i
9/6/2016Canaccord GenuitySet Price TargetBuy$110.00N/A
i
Rating by john newman at Canaccord Genuity
8/12/2016BMO Capital MarketsReiterated RatingBuy$57.00N/A
i
Rating by Gary Nachman at BMO Capital Markets
7/15/2016William BlairReiterated RatingOutperform$75.00N/A
i
Rating by Tim Lugo at William Blair
7/12/2016JPMorgan Chase & Co.Reiterated RatingBuy$71.00N/A
i
Rating by Cory Kasimov at JPMorgan Chase & Co.
7/12/2016CowenReiterated RatingBuyN/A
i
Rating by Ritu Baral at Cowen Inc
7/12/2016Chardan CapitalReiterated RatingSellN/A
i
Rating by Gbola Amusa MD CFA at Chardan Capital
7/12/2016BMO Capital MarketsReiterated RatingBuyN/A
i
Rating by Gary Nachman at BMO Capital Markets
7/12/2016SVB LeerinkReiterated RatingBuy$66.00N/A
i
Rating by Paul Matteis at SVB Leerink LLC
6/28/2016BMO Capital MarketsInitiated CoverageOutperform$48.00N/A
i
6/23/2016HC WainwrightInitiated CoverageBuy$56.00N/A
i
Rating by C. Werther at HC Wainwright
6/21/2016SVB LeerinkReiterated RatingOutperform$66.00N/A
i
Rating by Paul Matteis at SVB Leerink LLC
6/8/2016Canaccord GenuityReiterated RatingBuyN/A
i
Rating by John Newman at Canaccord Genuity
6/8/2016CowenReiterated RatingBuyN/A
i
Rating by Ritu Baral at Cowen Inc
6/8/2016Chardan CapitalReiterated RatingSellN/A
i
Rating by Gbola Amusa MD CFA at Chardan Capital
5/27/2016Canaccord GenuityReiterated RatingBuyN/A
i
Rating by John Newman at Canaccord Genuity
5/24/2016Chardan CapitalInitiated CoverageSell$18.00N/A
i
5/16/2016SVB LeerinkReiterated RatingBuyN/A
i
Rating by Paul Matteis at SVB Leerink LLC
5/14/2016Canaccord GenuityReiterated RatingBuyN/A
i
Rating by John Newman at Canaccord Genuity
5/13/2016CowenReiterated RatingBuyN/A
i
Rating by Ritu Baral at Cowen Inc
5/8/2016Canaccord GenuityReiterated RatingBuy$110.00N/A
i
Rating by John Newman at Canaccord Genuity
4/8/2016SVB LeerinkReiterated RatingBuy$66.00N/A
i
Rating by Paul Matteis at SVB Leerink LLC
4/1/2016Goldman Sachs GroupReiterated RatingBuy$63.00N/A
i
Rating by Salveen Richter at Goldman Sachs Group Inc
3/30/2016Goldman Sachs GroupInitiated CoverageNeutral$83.00N/A
i
3/27/2016William BlairReiterated RatingBuyN/A
i
Rating by Tim Lugo at William Blair
3/24/2016Canaccord GenuityReiterated RatingBuy$110.00N/A
i
Rating by John Newman at Canaccord Genuity
3/11/2016Lake Street CapitalInitiated CoverageBuy$90.00N/A
i
Rating by C. Byrnes at Lake Street Capital
2/26/2016SVB LeerinkLower Price Target$66.00N/A
i
Rating by Paul Matteis at SVB Leerink LLC
2/25/2016William BlairLower Price TargetOutperform$58.00N/A
i
Rating by Tim Lugo at William Blair
2/24/2016Canaccord GenuityReiterated RatingBuyN/A
i
Rating by John Newman at Canaccord Genuity
2/24/2016JPMorgan Chase & Co.Reiterated RatingBuyN/A
i
Rating by Cory Kasimov at JPMorgan Chase & Co.
2/24/2016CowenReiterated RatingBuy$108.00 ➝ $95.00N/A
i
2/9/2016Canaccord GenuityReiterated RatingBuyN/A
i
Rating by John Newman at Canaccord Genuity
1/11/2016JPMorgan Chase & Co.Reiterated RatingOverweightN/A
i
Rating by Cory Kasimov at JPMorgan Chase & Co.
12/15/2015Canaccord GenuityReiterated RatingBuy$110.00N/A
i
Rating by John Newman at Canaccord Genuity
11/7/2015SVB LeerinkReiterated RatingBuyN/A
i
Rating by Paul Matteis at SVB Leerink LLC
11/6/2015SVB LeerinkReiterated RatingOutperform$107.00 ➝ $80.00N/A
i
Rating by Paul Matteis at SVB Leerink LLC
(Data available from 10/24/2015 forward)
Sage Therapeutics logo
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system (CNS) disorders. Its lead product candidate is ZULRESSO, a proprietary intravenous formulation of brexanolone for the treatment of postpartum depression (PPD). The company's product pipeline also includes SAGE-217, a novel neuroactive steroid, which is in Phase III clinical trials for treating PPD, major depressive disorders, bipolar depression, and generalized anxiety disorders; and SAGE-324, a novel compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epileptiform disorders and Parkinson's diseases. In addition, its product pipeline comprises SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which has completed Phase I clinical trial for the treatment of depression, Huntington's disease, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. Further, the company is developing SAGE-904, an oral therapy that is in Phase I clinical trial for disorders associated with NMDA hypofunction; and SAGE-689 for intramuscular administration. Sage Therapeutics, Inc. has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of SAGE-217 in Japan, Taiwan, and South Korea. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $71.51
$70.34
$72.10

50 Day Range

MA: $60.71
$51.03
$70.82

52 Week Range

Now: $71.51
$25.01
$155.33

Volume

371,822 shs

Average Volume

626,395 shs

Market Capitalization

$3.72 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.45